Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tovinontrine (Primary)
  • Indications Heart failure
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Cycle-1-REF
  • Sponsors Cardurion Pharmaceuticals; Enliven Therapeutics; Imara Inc

Most Recent Events

  • 27 Aug 2026 According to a Cardurion Pharmaceuticals media release, Company will present results from the Phase 2 CYCLE clinical trials in late-breaking presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona taking place on October 9 to 12, 2026.
  • 17 Nov 2025 Status changed from active, no longer recruiting to completed.
  • 06 Aug 2025 According to a Cardurion Pharmaceuticals media release, company announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in both types of chronic heart failure (HFrEF and HFpEF). James Udelson, MD is Principal Investigator for the CYCLE-1-REF and CYCLE-2-PEF trials. Results from these trial will be presenting at a future medical meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top